Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 1 of 4 PageID #: 555

Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 1 of 4 PageID #: 550

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC.,)		EALED
Plaintiff,)		
v.)	C.A. No. 14-914-GMS	
FRESENIUS KABI USA, LLC,)	CONFIDENTIAL— FILED UNDER SEAL	
Defendant.	í		

CONSENT JUDGMENT

Jack B. Blumenfeld (No. 1014)
Maryellen Noreika (No. 3208)
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com
Attorneys for Plaintiff Cubist
Pharmaceuticals, Inc.

OF COUNSEL:
William F. Lee
Lisa J. Pirozzolo
Emily R. Whelan
Sean K. Thompson
Ryann M. Muir
WILMER CUTLER PICKERING HALE
AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000

Dated: January 29, 2016

Karen E. Keller (No. 4489)
Jeffrey T. Castellano (#4837)
SHAW KELLER LLP
300 Delaware Avenue, Suite 1120
Wilmington, DE 19802
(302) 298-0700
kkeller@shawkeller.com
jcastellano@shawkeller.com
Attorneys for Defendant Fresenius Kabi USA,
LLC

OF COUNSEL:
Elizabeth J. Holland
Robert V. Cerwinski
Daniel P. Margolis
Linnea P. Cipriano
Aviv Zalcenstein
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
(212) 813-8800



Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 2 of 4 PageID #: 556

Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 2 of 4 PageID #: 551

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC.,)	
Plaintiff,)	
v.)	C.A. No. 14-914-GMS
FRESENIUS KABI USA, LLC,)	CONFIDENTIAL—
Defendant.)	FILED UNDER SEAL

CONSENT JUDGMENT

Plaintiff Cubist Pharmaceuticals, Inc. ("Plaintiff") and Defendant Fresenius Kabi USA, LLC ("Defendant"), by their undersigned counsel, stipulate and agree as follows:

WHEREAS Defendant submitted Abbreviated New Drug Application No. 206077 (together with any amendments or supplements thereto, "Defendant's ANDA") to obtain approval from the FDA to engage in the commercial manufacture, use and/or sale of the generic daptomycin injectable product described therein ("Defendant's ANDA Product"); and

WHEREAS Plaintiff represents that it owns Patent No. 6,468,967 (the "'967 Patent"), Patent No. 6,852,689 (the "'689 Patent"), Patent No. 8,058,238 (the "'238 Patent"), and Patent No. 8,129,342 (the "'342 Patent"); and

WHEREAS Plaintiff represents that it holds approved New Drug Application No. 21572 for CUBICIN® injectable, IV (infusion), 500 mg/vial, which contains the active ingredient daptomycin; and

WHEREAS Plaintiff has asserted in *Cubist Pharmaceuticals, Inc., v. Fresenius Kabi*USA, LLC, C.A. No. 14-914-GMS (D. Del.) ("this Litigation") that the filing of Defendant's ANDA infringes (directly or indirectly) and/or the commercial manufacture, use, offer for sale, sale and/or importation of Defendant's ANDA Product would infringe (directly or indirectly)



Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 3 of 4 PageID #: 557

Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 3 of 4 PageID #: 552

claims 91, 98, and 187 of the '238 Patent, claims 23 and 53 of the '342 Patent, claims 16-17 and 34-35 of the '967 Patent, and claims 51-52 of the '689 Patent (collectively the "Asserted Claims"); and

WHEREAS the Court in *Cubist Pharmaceuticals, Inc. v. Hospira, Inc.*, No. 12-CV-00367 (the "*Hospira* Action") issued a Memorandum Opinion and Judgment after trial holding that all of the Asserted Claims are invalid (*Hospira* Judgment); and

WHEREAS Plaintiff appealed the *Hospira* Judgment to the U.S. Court of Appeals for the Federal Circuit in *Cubist Pharmaceuticals, Inc. v. Hospira, Inc.*, Nos. 2015-1197, -1204, -1259 (the "*Hospira* Appeal"); and

WHEREAS the Federal Circuit has affirmed in the *Hospira* Appeal that the Asserted Claims are invalid;

Now, THEREFORE, Plaintiff and Defendant consent to the entry of judgment as follows:

- 1. The Asserted Claims are invalid;
- 2. Plaintiff's claims in this Litigation are dismissed with prejudice in their entirety.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

SHAW KELLER LLP

/s/ Jack B. Blumenfeld

/s/ Karen E. Keller

Jack B. Blumenfeld (No.1014)
Maryellen Noreika (No. 3208)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com
Attorneys for Plaintiff Cubist
Pharmaceuticals, Inc.

Karen E. Keller (No. 4489)
Jeffrey T. Castellano (No. 4837)
300 Delaware Avenue, Suite 1120
Wilmington, DE 19802
(302) 298-0700
kkeller@shawkeller.com
jcastellano@shawkeller.com
Attorneys for Defendant Fresenius Kabi USA,
LLC



Case 1:14-cv-00914-GMS Document 81 Filed 02/02/16 Page 4 of 4 PageID #: 558

Case 1:14-cv-00914-GMS Document 79 *SEALED* Filed 01/29/16 Page 4 of 4 PageID #: 553

OF COUNSEL:
William F. Lee
Lisa J. Pirozzolo
Emily R. Whelan
Sean K. Thompson
Ryann M. Muir
WILMER CUTLER PICKERING HALE
AND DORR LLP
60 State Street
Boston, MA 02109

(617) 526-6000

OF COUNSEL:
Elizabeth J. Holland
Robert V. Cerwinski
Daniel P. Margolis
Linnea P. Cipriano
Aviv Zalcenstein
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
(212) 813-8800

IT IS SO ORDERED 2 day of July 2016.

United States District Judge